DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy People

Information source: Solvay Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Volunteers

Intervention: Fenofibrate 160 mg tablet (Drug); Placebo (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Solvay Pharmaceuticals

Official(s) and/or principal investigator(s):
Global Clinical Director Solvay, Study Director, Affiliation: Solvay Pharmaceuticals

Summary

The purpose of this study was to test the effect of fenofibrate treatment on glomerular filtration rate (GFR), kidney hemodynamics and tubular function in middle-aged subjects with normal kidney function to further investigate the increase in creatinine levels observed in fenofibrate-treated subjects.

Clinical Details

Official title: A Double-blind, Cross-over, Placebo-controlled Study Evaluating the Effect of Fenofibrate 160 mg Tablets on Glomerular Filtration Rate and Other Renal Function Test in Healthy Subjects

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Glomerular filtration rate (GFR) assessed by the measure of inulin clearance

Secondary outcome:

GFR evaluated by raw values of plasma creatinine and cystatin C levels

Renal haemodynamics evaluated by raw values of renal plasma and blood flows

Tubular function: creatinine clearance, albuminuria, urine N-acetyl Beta D glucosaminidase and Retinol Binding Protein, sodium clearance and sodium fractional excretion

Other functions : blood and urine urea, total proteins, albumin, uric acid, Na+, K+, blood fasting glucose, urinary creatinine, erythrocytes, leukocytes, casts and Calculated osmolarity, free water and urinary urate

Eligibility

Minimum age: 30 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male and female

- Age: 30-60 years old

- Subjects with normal renal function as documented by: Plasma creatinine < 130 µmol/L,

AND Cockcroft & Gault creatinine clearance (Co Cr CL) >80 ml/min

- Certified as normal by a comprehensive medical assessment and laboratory

investigations the results of which are within the normal range /or clinically acceptable for the present subjects and who have a negative urinary screen for drugs of abuse.

- Written informed consent

Exclusion Criteria:

- Body Mass Index (BMI) ≥ 30 kg/m² or <18 kg/m².

- Pregnant, breast-feeding, or woman with child bearing potential without a reliable

method of contraception.

- Having received an investigational drug in the last 90 days before date of inclusion.

- With known hypersensitivity to fibrates.

- Unable or unwilling to comply with the protocol, or likely to leave the study before

its completion.

- Who would undertake important change in physical exercise or vigorous sport

competitions during the study period.

- Drug therapies are not permitted during the study, except contraceptive pill when

applicable, with the exception of occasional use of paracetamol.

- Any administration of treatment, which could bring about induction or inhibition of

hepatic microsomal enzymes within 3 months of the study start.

- Diabetes mellitus, Heart diseases, Kidney diseases, hypertension, asthma, Liver

diseases, Chronic pancreatitis, or identified risk or known history of acute pancreatitis, Known cholelithiasis without cholecystectomy, ASAT and/or ALAT > 1. 3 times ULN, Gastric or peptic ulcer or intestinal diseases, Musculoskeletal diseases or increased CK > 1. 0 times ULN, History of neoplasm, Mental illness, Regular user of sedatives, hypnotics, tranquillisers or any other addictive agents or who are known to be prone to alcohol abuse (i. e. history or evidence of acute abuse), or alcohol intake >14 units per week (unit = ½ pint of beer, 1 glass of wine, 2,5 cl standard spirits), or heavy smokers (>10 cigarettes/day), or excessive drinker of tea, coffee and/or beverages containing caffeine (>8 cups/day), Blood donor with recent donation (in the three months preceding the initiation of the study) or would make blood donations during the study, Blood transfusion or administration of blood-derived products, in the year preceding the study.

Locations and Contacts

Site 1, London, United Kingdom
Additional Information

Starting date: August 2002
Last updated: January 16, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017